PDF Archive search engine
Last database update: 18 May at 13:36 - Around 76000 files indexed.
Spanish, German Research interests My main research interests have been a combination of clinical and basic cancer research (translational), including biomarkers for early detection of cancer, predictive and prognostic biomarkers, genome-wide analysis and mechanisms of treatment resistance.
2ND r INTERNATIONAL NTNU SYMPOS UM 5 CURRENT AND FUTURE CLINICAL BIOMARKERS OF CANCER NTE i RNR T I ON H NTNU L SYMPOSIUMON i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i C L(N I Cfi L B l0M RRKERSO FCANCER From diagnosis to immunotherapy - why is precision medicine so difficult?
ESMO ADVANCED COURSE PROGRAMME LUNG CANCER IN IMMUNOTHERAPY A NEW PARADIGM WITH UNANSWERED QUESTIONS Zurich, Switzerland 3-4 July 2019 CO-CHAIRS Aurelien Marabelle, France SPEAKERS John Haanen, Netherlands Maurice Perol, France Solange Peters, Switzerland David Planchard, France LEARNING OBJECTIVES Understanding the key players in tumour immunology Getting up-to-date on the role of immunotherapy in advanced NSCLC The role of biomarkers in selecting NSCLC patients for IT Mechanism of combining angiogenesis inhibition with checkpoint inhibition Management of IT toxicity and use of IT in specific subgroups of patients ACCREDITATION The programme of this event has been accredited with 10 ESMO-MORA category 1 points.
A MULTIANALYTE ALGORITHM PCR-BASED BLOOD TEST OUTPERFORMS SINGLE ANALYTE ELISA-BASED BLOOD TESTS FOR NEUROENDOCRINE TUMOR DETECTION A key issue in management of neuroendocrine tumors (NETs) is specific and sensitive biomarkers.
www.openmedscience.com Commentary Article Choosing a target for targeted radionuclide therapy using biomarkers to personalize treatment William C.
Quantitative neuroimaging has recently revealed disrupted brain networks in migraine, and discovering such neuroimaging biomarkers may enlighten disease mechanisms and guide future disease-modifying clinical trials.
PD-1 targeting immunotherapy in NSCLC 15:20 - 15:40 20min Salvage PD-1 targeting therapy in unselected NSCLC 15:40 - 16:00 20min PD-L1 as a biomarker for PD-1 targeting therapy 16:00 - 16:20 20min Other biomarkers for PD-1 targeting therapy 16:20 - 16:30 10min Q&A 16:30 - 16:40 10min Closing remark KCSG 두경부암 분과장 윤환중 등록 및 식사안내 교통 및 주차 안내 ▶▶ 등록비 ▶▶ 오시는 구 사전등록 현장등록 교수, 전문의, 박사급 연구원 30,000원 40,000원 전임의, 전공의, 간호사 석사급 이하 연구원 및 학생 공보의, 군의관 20,000원 30,000원 교수, 전문의, 박사급 연구원 40,000원 50,000원 전임의, 전공의, 간호사 석사급 이하 연구원 및 학생 공보의, 군의관 30,000원 40,000원 기타, 업체 참가 50,000원 60,000원 좌장:
Reverse-engineering of biomarkers development patterns:
updated classification, molecular insights, biomarkers and targeted therapy Dr.
Sword ELISA Booster Sword Diagnostics is developing a new plug-in performance booster for ELISA assays to enable trace detection of biomarkers and offer researchers:
Clinical biomarkers of Alzheimer’s Disease include amyloid-beta plaques and tau neurofibrillary tangles.
NUCLEOSIDE TRANSPORTERS AS CHEMOTHERAPEUTIC TARGETS AND BIOMARKERS OF DRUG RESPONSE 1 M ovement of physiologic nucleosides and hydrophilic nucleoside analogues across biological membranes is mediated by nucleoside transport proteins.
ERC-2016-PoC-DL3 “Advanced platform for profiling of therapeutic targets and functional analysis of circulating tumour cells in cancer patients” DISSECT, 8/2011 – 7/2016, 60 calendar months ERC Advanced Investigator Grant ERC-2010-AsG_20100317 “Disseminating tumour cells as novel biomarkers:
Anthony Zietman, MD 10:45 am Biomarkers to select patients for active surveillance vs treatment Speaker:
9. Frankfurter Lungenkrebskongress 07.
Management of brain metastasis in NSCLC patients with driver mutation 홍민희(연세의대) 15min Case presentation 안희경(가천의대) 10:45-11:10 25min Radiation oncologist's perspective 노재명(성균관의대) 11:10-11:35 25min Medical oncologist's perspective 최윤지(고려의대) 11:35-11:50 15min Discussion and voting 11:50-12:10 20min Coffee break Luncheon Symposium 40min Biomarkers in lung cancer: